we are an immuno-oncology cell therapy company focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. our name, 2seventy bio, is inspired by the maximum speed of translating human thought into action—270 miles per hour, and at 2seventy, we think in the language of time. with a deep understanding of cancer cell metabolism, genomics, and the human body’s immune response to tumor cells, we’re applying this knowledge and expertise to new classes of cellular therapies that are designed to “think” smarter and faster than cancer. it is this mindset that propels us forward because we know that time matters -- every day, every minute, every second -- to people living with cancer
![2seventy bio logo](/files/LOGO/1860782-TSVT.png)
Company profile
Ticker
TSVT
Exchange
Website
CEO
Nick Leschly
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
2seventy bio Securities Corporation ...
IRS number
863658454
TSVT stock data
Latest filings (excl ownership)
8-K
Results of Operations and Financial Condition
26 Jul 24
8-K
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
26 Jun 24
8-K
Unleash Time2seventy bio company presentation May 2024
11 Jun 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
8 May 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K
Results of Operations and Financial Condition
25 Apr 24
8-K
Other Events
9 Apr 24
Transcripts
TSVT
Earnings call transcript
2024 Q1
8 May 24
TSVT
Earnings call transcript
2023 Q4
5 Mar 24
TSVT
Earnings call transcript
2023 Q3
14 Nov 23
TSVT
Earnings call transcript
2023 Q2
14 Aug 23
TSVT
Earnings call transcript
2023 Q2
14 Aug 23
TSVT
Earnings call transcript
2023 Q1
3 May 23
TSVT
Earnings call transcript
2023 Q1
3 May 23
TSVT
Earnings call transcript
2022 Q2
10 Aug 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 57.03 mm | 57.03 mm | 57.03 mm | 57.03 mm | 57.03 mm | 57.03 mm |
Cash burn (monthly) | 6.55 mm | 11.50 mm | 17.56 mm | 19.88 mm | 13.96 mm | 13.30 mm |
Cash used (since last report) | 25.33 mm | 44.48 mm | 67.88 mm | 76.86 mm | 53.97 mm | 51.44 mm |
Cash remaining | 31.69 mm | 12.54 mm | -10.86 mm | -19.84 mm | 3.06 mm | 5.59 mm |
Runway (months of cash) | 4.8 | 1.1 | -0.6 | -1.0 | 0.2 | 0.4 |
Institutional ownership, Q1 2024
3.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 18 |
Closed positions | 5 |
Increased positions | 2 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 8.65 bn |
Total shares | 1.54 mm |
Total puts | 25.50 k |
Total calls | 43.90 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Cowen And | 800.00 k | $4.28 bn |
BK Bank Of New York Mellon | 186.88 k | $999.82 mm |
Mirae Asset Global Investments | 146.90 k | $1.35 bn |
Susquehanna Fundamental Investments | 138.24 k | $739.60 mm |
Wedmont Private Capital | 85.93 k | $483.81 mm |
Exchange Traded Concepts | 71.95 k | $384.95 mm |
Susquehanna International | 33.04 k | $176.74 mm |
SG Americas Securities | 17.44 k | $93.00 k |
New York State Common Retirement Fund | 17.33 k | $93.00 k |
PFG Principal Financial Group Inc - Registered Shares | 14.34 k | $76.70 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jul 24 | Victoria Eatwell | Common Stock | Sell | Dispose S | No | No | 4.0178 | 12 | 48.21 | 341,332 |
2 Jul 24 | Jessica Snow | Common Stock | Sell | Dispose S | No | No | 4.0178 | 14 | 56.25 | 164,146 |
1 Jul 24 | Victoria Eatwell | Common Stock | Grant | Acquire A | No | No | 0 | 245,864 | 0.00 | 341,344 |
1 Jul 24 | William D Baird III | Common Stock | Grant | Acquire A | No | No | 0 | 586,022 | 0.00 | 894,607 |
1 Jul 24 | Jessica Snow | Common Stock | Grant | Acquire A | No | No | 0 | 108,538 | 0.00 | 164,160 |
10 Jun 24 | Casdin Capital | Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 0 | 6,025 | 0.00 | 22,625 |
10 Jun 24 | Casdin Capital | Stock Options Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 3.93 | 12,050 | 47.36 k | 12,050 |
10 Jun 24 | Charles W. Newton | Common Stock | Grant | Acquire A | No | No | 0 | 6,025 | 0.00 | 22,625 |
10 Jun 24 | Charles W. Newton | Stock Options Common Stock | Grant | Acquire A | No | No | 3.93 | 12,050 | 47.36 k | 12,050 |